← Back to Clinical Trials
Recruiting NCT07346092

NCT07346092 Studying the Health Perceptions and Social Behaviors of Graduate Students at the Ohio State University for the Development of Effective Oral Nicotine Pouch Addictive Risk Communication

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07346092
Status Recruiting
Phase
Sponsor Ohio State University Comprehensive Cancer Center
Condition Tobacco-Related Carcinoma
Study Type INTERVENTIONAL
Enrollment 2,000 participants
Start Date 2025-03-20
Primary Completion 2027-03-20

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Preventive InterventionPreventive InterventionPreventive Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,000 participants in total. It began in 2025-03-20 with a primary completion date of 2027-03-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial studies the health perceptions and social behaviors of Ohio State University (OSU) graduate students to develop an interactive, social norms-based approach that is effective in communicating the addictive risks of oral nicotine pouches (ONPs). The use of ONPs is rising rapidly among young adults (YA). Various factors contribute to the growing popularity of ONPs, including their affordability, accessibility both online and in physical stores, discreet use, and heavy internet advertising. However, for those who are experimenting, have tried ONPs in the past, or have never used them but are surrounded by others who do, factors like affordability and availability may not be the only reasons for initiating or continuing use. Social norms are also a significant factor influencing YA tobacco use. Peer influence on college campuses and in other social environments may encourage YA to conform to behaviors they perceive as popular or acceptable. Being surrounded by peers who use ONPs may create pressure to try them, especially as YA seek to fit in within their social circles. Studying the health perceptions and social behaviors of OSU graduate students may help researchers develop an interactive, social norms-based approach that is effective in communicating the addictive risks of ONPs.

Eligibility Criteria

Inclusion Criteria: * AIM 1: OSU graduate students aged 21 years or older * AIM 2 AND 3: Students identified in Aim 1 as susceptible to ONPs, having experimented with ONPs, or currently using ONPs-those considered at high risk for nicotine dependence-will be invited to participate in Aim 2 or Aim 3 * AIM 3: Participants in Aim 2 will not be invited to participate in Aim 3, as they will have already been exposed to the experimental stimuli

Contact & Investigator

Central Contact

The Ohio State University Comprehensive Cancer Center

✉ OSUCCCClinicaltrials@osumc.edu

📞 1-800-293-5066

Principal Investigator

Megan E Roberts, PhD

PRINCIPAL INVESTIGATOR

Ohio State University Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT07346092 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Tobacco-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07346092 currently recruiting?

Yes, NCT07346092 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.

Where is the NCT07346092 trial being conducted?

This trial is being conducted at Columbus, United States.

Who is sponsoring the NCT07346092 clinical trial?

NCT07346092 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Megan E Roberts, PhD at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology